EHA: European Hematology Association

Conference Coverage

CTL019 produces responses in rel/ref DLBCL

The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory...

Conference Coverage

Less is more in PET-negative, advanced HL

MADRID—Patients with advanced Hodgkin lymphoma (HL) who are PET-negative after initial treatment with 2 cycles of eBEACOPP* should only receive 2...

Conference Coverage

Midostaurin improves survival in new AML

Adding the multitargeted kinase inhibitor midostaurin to standard chemotherapy led to significantly longer overall and event-free survival...

Conference Coverage

Ibrutinib dons new anti-GVHD hat

MADRID – Talk about versatility: Ibrutinib (Imbruvica), a drug with marked activity against B-cell malignancies, also appears to be a safe and...